The estimated Net Worth of Jerzy Gumulka is at least $6.88 millier dollars as of 1 February 2024. Jerzy Gumulka owns over 33,333 units of Cns Pharmaceuticals Inc stock worth over $6,881 and over the last 4 years Jerzy sold CNSP stock worth over $0.
Sign up
Jerzy Gumulka CNSP stock SEC Form 4 insiders trading
Jerzy has made over 3 trades of the Cns Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jerzy bought 33,333 units of CNSP stock worth $10,000 on 1 February 2024.
The largest trade Jerzy's ever made was buying 33,333 units of Cns Pharmaceuticals Inc stock on 1 February 2024 worth over $10,000. On average, Jerzy trades about 6,144 units every 42 days since 2020. As of 1 February 2024 Jerzy still owns at least 43,006 units of Cns Pharmaceuticals Inc stock.
You can see the complete history of Jerzy Gumulka stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jerzy Gumulka's mailing address?
Jerzy's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.
Insiders trading at Cns Pharmaceuticals Inc
Over the last 5 years, insiders at Cns Pharmaceuticals Inc have traded over $132,960 worth of Cns Pharmaceuticals Inc stock and bought 509,021 units worth $458,622 . The most active insiders traders include Christopher Downs, John M Climaco et Waldemar Priebe. On average, Cns Pharmaceuticals Inc executives and independent directors trade stock every 79 days with the average trade being worth of $6,051. The most recent stock trade was executed by Jerzy Gumulka on 1 February 2024, trading 33,333 units of CNSP stock currently worth $10,000.
What does Cns Pharmaceuticals Inc do?
cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.
What does Cns Pharmaceuticals Inc's logo look like?
Complete history of Jerzy Gumulka stock trades at Cns Pharmaceuticals Inc
Cns Pharmaceuticals Inc executives and stock owners
Cns Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Michael Climaco Esq., J.D.,
Chairman, CEO & Pres -
Christopher S. Downs CPA, CTP, FP&A,
Chief Financial Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer -
Dr. Donald H. Picker Ph.D.,
Chief Science Officer -
Dr. Waldemar Priebe Ph.D.,
Founder & Chairman of the Scientific Advisory Board -
Amy Mahery,
Director -
Biosciences, Inc. Cortice,
-
Christopher Downs,
Chief Financial Officer -
Jerzy Gumulka,
Director -
Carl Anthony Evans,
Director -
Jeffry R. Keyes,
Director -
John M Climaco,
Chief Executive Officer -
Waldemar Priebe,
-
Faith L. Charles,
Director -
Bettina M. Cockroft,
Director